Fig. 7: MiR-142-3p enhanced the anti-tumour effects of sorafenib in HCC in vivo. | Cell Death & Disease

Fig. 7: MiR-142-3p enhanced the anti-tumour effects of sorafenib in HCC in vivo.

From: PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib

Fig. 7: MiR-142-3p enhanced the anti-tumour effects of sorafenib in HCC in vivo.

a Growth curves for tumour volumes and representative photographs of tumour-bearing mice. b Representative photographs of tumour and tumour weight. c ATG5 and ATG16L1 expression levels were analysed by immunostaining in HepG2/miR-142-3p and HepG2/control xenografts after sorafenib therapy. Immunostaining and TUNEL staining were employed to measure PCNA and Ki67 levels, as well as apoptosis rates, in tumours derived from HepG2/miR-142-3p and HepG2/control xenografts after sorafenib therapy. d Western blotting was performed to assess LC3, ATG5, ATG16L1 and p62 protein expression in tumours derived from HepG2/miR-142-3p and HepG2/control xenografts after sorafenib therapy. All data are represented as the mean ± S.D. from three independent experiments. The p-values represent comparisons between groups (*p < 0.05, **p < 0.01)

Back to article page